ENZASTAURIN AND FRAGILE HISTIDINE TRIAD (FHIT)-INCREASING AGENTS FOR THE TREATMENT OF PULMONARY HYPERTENSION

The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients...

Full description

Saved in:
Bibliographic Details
Main Authors SPIEKERKOETTER, Edda, DANNEWITZ PROSSEDA, Svenja, TIAN, Xuefei, KHATRI, Purvesh
Format Patent
LanguageEnglish
Published 02.07.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients for treatment or to monitor effectiveness of treatment. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems, and that it acts by up-regulation of FHIT and/or BMPR2.
Bibliography:Application Number: US201816614778